JP2021533201A - Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療 - Google Patents

Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療 Download PDF

Info

Publication number
JP2021533201A
JP2021533201A JP2021529491A JP2021529491A JP2021533201A JP 2021533201 A JP2021533201 A JP 2021533201A JP 2021529491 A JP2021529491 A JP 2021529491A JP 2021529491 A JP2021529491 A JP 2021529491A JP 2021533201 A JP2021533201 A JP 2021533201A
Authority
JP
Japan
Prior art keywords
tent
peg
pegylated
kda
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021529491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533201A5 (https=
JPWO2020024002A5 (https=
Inventor
マクリーン，トーマス
スムーカー，ピーター
ノーブリー，ルーク
コロエ，ピーター
コンジット，ラッセル
サッセ，アンソニー
Original Assignee
スノーレトックス プロプライエタリー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018902779A external-priority patent/AU2018902779A0/en
Application filed by スノーレトックス プロプライエタリー リミテッド filed Critical スノーレトックス プロプライエタリー リミテッド
Publication of JP2021533201A publication Critical patent/JP2021533201A/ja
Publication of JP2021533201A5 publication Critical patent/JP2021533201A5/ja
Publication of JPWO2020024002A5 publication Critical patent/JPWO2020024002A5/ja
Priority to JP2023196375A priority Critical patent/JP7786745B2/ja
Priority to JP2025203043A priority patent/JP2026026159A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
JP2021529491A 2018-07-31 2019-07-30 Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療 Pending JP2021533201A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023196375A JP7786745B2 (ja) 2018-07-31 2023-11-20 Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療
JP2025203043A JP2026026159A (ja) 2018-07-31 2025-11-25 Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018902779 2018-07-31
AU2018902779A AU2018902779A0 (en) 2018-07-31 Composition and method
PCT/AU2019/050793 WO2020024002A1 (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023196375A Division JP7786745B2 (ja) 2018-07-31 2023-11-20 Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療

Publications (3)

Publication Number Publication Date
JP2021533201A true JP2021533201A (ja) 2021-12-02
JP2021533201A5 JP2021533201A5 (https=) 2022-08-05
JPWO2020024002A5 JPWO2020024002A5 (https=) 2022-08-05

Family

ID=69230503

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021529491A Pending JP2021533201A (ja) 2018-07-31 2019-07-30 Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療
JP2023196375A Active JP7786745B2 (ja) 2018-07-31 2023-11-20 Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療
JP2025203043A Pending JP2026026159A (ja) 2018-07-31 2025-11-25 Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023196375A Active JP7786745B2 (ja) 2018-07-31 2023-11-20 Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療
JP2025203043A Pending JP2026026159A (ja) 2018-07-31 2025-11-25 Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療

Country Status (12)

Country Link
US (1) US20210353724A1 (https=)
EP (2) EP4134133A1 (https=)
JP (3) JP2021533201A (https=)
KR (1) KR20210040407A (https=)
CN (2) CN120661638A (https=)
AU (1) AU2019315327B2 (https=)
BR (1) BR112021001520A2 (https=)
CA (2) CA3167665A1 (https=)
MX (1) MX2021001181A (https=)
NZ (1) NZ772266A (https=)
SG (1) SG11202100646SA (https=)
WO (1) WO2020024002A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240268895A1 (en) 2023-02-15 2024-08-15 Canon Medical Systems Corporation X-ray diagnostic apparatus, x-ray diagnostic system, and x-ray diagnostic method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020197278A1 (en) * 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
JP2003503059A (ja) * 1999-06-25 2003-01-28 インペリアル カレッジ オブ サイエンス， テクノロジー アンド メディシン 破傷風毒素ポリペプチド
JP2004521067A (ja) * 2000-06-28 2004-07-15 サンダース，イラ 動物（哺乳動物）における有用な用途を目的とする破傷風毒素の使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003200441B2 (en) * 1998-04-29 2006-07-06 Allergan, Inc. Compositions and methods for modulating neural sprouting
AU2003237346A1 (en) * 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
WO2008024879A1 (en) * 2006-08-25 2008-02-28 University Of Maryland, Baltimore Use of tetanus toxin to amplify inadequate voluntary muscle contraction or to improve muscle tone in an animal actively vaccinated against the toxin and a regimen for treatment
KR101818777B1 (ko) * 2009-04-27 2018-01-15 메르츠 파마 게엠베하 운트 코. 카가아 신경독 폴리펩티드의 양 및 이들의 촉매 활성 및 단백질 분해 활성의 결정수단 및 방법
ES2616258T3 (es) * 2010-03-15 2017-06-12 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna
US20170151316A1 (en) * 2014-07-02 2017-06-01 Spherium Biomed, S.L. Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc)
US10704035B2 (en) * 2015-08-27 2020-07-07 President And Fellows Of Harvard College Compositions and methods for treatment of pain
CN106692963B (zh) * 2016-12-28 2020-12-22 中国人民解放军军事医学科学院生物工程研究所 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗
EP3723784A4 (en) * 2017-12-15 2022-01-12 The Medical College of Wisconsin, Inc. USE OF MODIFIED CLOSTRIDIAL NEUROTOXINS AS VACCINES AND CONJUGATE VACCINE PLATFORMS
WO2021155427A1 (en) * 2020-02-03 2021-08-12 Snoretox Pty Ltd Composition and method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003503059A (ja) * 1999-06-25 2003-01-28 インペリアル カレッジ オブ サイエンス， テクノロジー アンド メディシン 破傷風毒素ポリペプチド
JP2004521067A (ja) * 2000-06-28 2004-07-15 サンダース，イラ 動物（哺乳動物）における有用な用途を目的とする破傷風毒素の使用方法
US20020197278A1 (en) * 2001-06-21 2002-12-26 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol

Also Published As

Publication number Publication date
CA3108079C (en) 2023-10-10
EP3830110A1 (en) 2021-06-09
AU2019315327B2 (en) 2024-05-09
NZ772266A (en) 2022-09-30
CA3108079A1 (en) 2020-02-06
US20210353724A1 (en) 2021-11-18
JP2024014975A (ja) 2024-02-01
WO2020024002A1 (en) 2020-02-06
KR20210040407A (ko) 2021-04-13
SG11202100646SA (en) 2021-02-25
MX2021001181A (es) 2021-04-19
NZ789962A (en) 2025-07-25
BR112021001520A2 (pt) 2021-04-20
CN112638937B (zh) 2025-06-17
EP4134133A1 (en) 2023-02-15
JP7786745B2 (ja) 2025-12-16
EP3830110A4 (en) 2022-03-02
AU2019315327A1 (en) 2021-02-11
CN120661638A (zh) 2025-09-19
CN112638937A (zh) 2021-04-09
JP2026026159A (ja) 2026-02-16
CA3167665A1 (en) 2020-02-06

Similar Documents

Publication Publication Date Title
ES2329232T3 (es) Tratamiento de trastornos y afecciones neuromusculares con un serotipo botulinico diferente.
ES2881301T3 (es) Neurotoxinas catiónicas
JP4557426B2 (ja) ボツリヌス毒素の安定な液体処方物
AU2009286973B2 (en) Clostridial neurotoxins with altered persistency
JP7007392B2 (ja) 唾液腺炎の治療におけるボツリヌス神経毒素の改善された使用
CN109890415A (zh) 多价肺炎球菌多糖-蛋白质缀合物组合物
JP2026026159A (ja) Ｐｅｇ化破傷風神経毒素および筋緊張低下の治療
US20230158100A1 (en) Treatment of panx1 associates diseases
TW202120530A (zh) 神經障礙之治療
JP2023513895A (ja) 組成物及び方法
TWI921701B (zh) 神經障礙之治療
Shepherd Generation of recombinant toxin molecules from Clostridium tetani and Clostridium botulinum
JP2025534349A (ja) 膀胱痛症候群の治療
CN121532207A (zh) 用于治疗特应性皮炎的主动免疫
WO2025051845A1 (en) Products and methods for inducing immune responses to bacteria
EA046580B1 (ru) Катионные нейротоксины
NZ715570B2 (en) Cationic neurotoxins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230620

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240130